Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Beta-lactams in ICU Patients
NCT03440216Unknown
- Sponsor
- UCLouvain
- Start
- Mar 2018
- Primary completion
- Oct 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Open-label trial of temocillin, ceftriaxone and meropenem in bacterial infection, pulmonary infection, Intra-abdominal infection (IAI) and 1 more (2 arms), sponsored by UCLouvain. Primary endpoint: Impact of renal function on total plasma concentrations at 36 months. Status: unknown.
02
Drugs
temocillinceftriaxonemeropenem
03
Conditions
bacterial infectionpulmonary infectionIntra-abdominal infection (IAI)sepsis
Beyond the preview
Go deeper on NCT03440216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440216.